Literature DB >> 8106140

Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis.

J S Ross1, T Nazeer, K Church, C Amato, H Figge, M D Rifkin, H A Fisher.   

Abstract

BACKGROUND: Recent advances in the early detection of prostatic adenocarcinoma have stimulated interest in the development of techniques for determining metastatic potential.
METHODS: One hundred cases of adenocarcinoma, including 66 biopsy and radical prostatectomy specimens; 20 biopsies alone; and 14 transurethral resection specimens, were evaluated for Gleason tumor grade, DNA content and HER-2/neu expression. DNA content was determined on Feulgen-stained touch preparations and tissue sections (18 cases) or tissue sections alone. HER-2/neu expression level was determined by image-analysis-assisted quantitative immunocytochemistry.
RESULTS: Tumor grade and ploidy status were independent significant predictors of metastasis. HER-2/neu overexpression was found in 16 (16%) of the 100 cases and significantly correlated with high-tumor grade and aneuploid status, but was not of independent value in the prediction of metastasis.
CONCLUSIONS: HER-2/neu overexpression is not uncommon in prostatic adenocarcinoma and is associated with high-tumor grade, abnormal DNA content, and distant metastasis. Tumor grade and DNA ploidy values are of the greatest value in determining the presence of metastasis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8106140     DOI: 10.1002/1097-0142(19931115)72:10<3020::aid-cncr2820721026>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer.

Authors:  Imran Ahmad; Rachana Patel; Lukram Babloo Singh; Colin Nixon; Morag Seywright; Robert J Barnetson; Valerie G Brunton; William J Muller; Joanne Edwards; Owen J Sansom; Hing Y Leung
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

2.  A tyrosine kinase profile of prostate carcinoma.

Authors:  D Robinson; F He; T Pretlow; H J Kung
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

3.  Analysis of protooncogene c-erbB-2 in benign and malignant human prostate.

Authors:  M Watanabe; T Nakada; H Yuta
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

4.  Her-2/neu oncogene amplification in clinically localised prostate cancer.

Authors:  J D Oxley; M H Winkler; D A Gillatt; D S Peat
Journal:  J Clin Pathol       Date:  2002-02       Impact factor: 3.411

Review 5.  Molecular biology of prostate cancer.

Authors:  X B Shi; P H Gumerlock; R W deVere White
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 6.  Molecular and genetic prognostic factors of prostate cancer.

Authors:  Arnab Chakravarti; Gary Guotang Zhai
Journal:  World J Urol       Date:  2003-08-09       Impact factor: 4.226

7.  Adrenocorticotropin-Producing Pituitary Carcinoma with Expression of c-erbB-2 and High PCNA Index: A Comparative Study with Pituitary Adenomas and Normal Pituitary Tissues.

Authors:  Vania Nose-Alberti; Maria Isabel S. Mesquita; Luciana C. Martin; Marcia J. Kayath
Journal:  Endocr Pathol       Date:  1998       Impact factor: 3.943

8.  A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer.

Authors:  N D James; P J Atherton; J Jones; A J Howie; S Tchekmedyian; R T Curnow
Journal:  Br J Cancer       Date:  2001-07-20       Impact factor: 7.640

9.  Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers.

Authors:  D Vernimmen; M Gueders; S Pisvin; P Delvenne; R Winkler
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.